halofenate has been researched along with rosiglitazone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allen, T; Bell, A; Clemens, LE; Gregoire, F; Gustafson, TA; Moodie, SA; Muscat, GE; Smith, A; Zhang, F | 1 |
| Beaumont, KA; Boyle, GM; Cook, AL; Muscat, GE; Parsons, PG; Smit, DJ; Smith, AG; Sturm, RA; Thurber, AE | 1 |
2 other study(ies) available for halofenate and rosiglitazone
| Article | Year |
|---|---|
Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Cell Differentiation; Cell Line; Diabetes Mellitus; Gene Expression Regulation; Halofenate; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands; Mice; Mice, Obese; PPAR gamma; Protein Structure, Tertiary; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Two-Hybrid System Techniques | 2006 |
PPARgamma agonists attenuate proliferation and modulate Wnt/beta-catenin signalling in melanoma cells.
Topics: Animals; Antineoplastic Agents; beta Catenin; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Chlorocebus aethiops; Chromans; COS Cells; Halofenate; Humans; Melanoma; PPAR gamma; RNA, Messenger; RNA, Small Interfering; Rosiglitazone; Signal Transduction; Thiazolidinediones; Troglitazone; Wnt Proteins | 2009 |